Study evaluates fluciclovine F-18 PET/CT imaging


Secondary analysis of data from the FALCON and LOCATE clinical trials showed fluciclovine F 18 PET/CT imaging, developed by Blue Earth Diagnostics, detected lesions in 58% of patients with recurrent prostate cancer, leading to treatment plan changes in 64% of cases, according to a study presented at the Global Summit on Precision Diagnosis and Treatment of Prostate Cancer. Androgen deprivation therapy was delayed or avoided in 59% of patients with treatment plan changes.

Full story:

SNMMI SmartBrief

Nuclear medicine, molecular imaging and therapy

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession.